Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025

Core Viewpoint - Vericel Corporation will report its third-quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results and business highlights [1]. Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care markets, combining biological innovations with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3]. - The company markets three products in the United States: - MACI®: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3]. - Epicel®: A permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3]. - NexoBrid®: A biological orphan product for eschar removal in patients with deep partial-thickness and/or full-thickness thermal burns, for which Vericel holds exclusive North American rights [3].